Skip to main content
NewslettersWatchlist

Diagnos Inc(ADK-X)
TSX Venture

Today's Change
Delayed Last Update
Day Low0.300
Day High0.310
Open:0.310
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
Automated Summaries - The Globe and Mail
Closing Bell: Diagnos Inc down on Thursday (ADK)
GlobeNewswire
DIAGNOS to expedite application for Medical Device License to Health Canada and US FDA related to its 4 new analysis modules, and is planning ISO 27001 certification
GlobeNewswire
DIAGNOS Inc. to Present at the AI & Technology Hybrid Investor Conference April 11th
GlobeNewswire
DIAGNOS Announces Grant of Stock Options
GlobeNewswire
DIAGNOS Welcomes Dr. Philippe Couillard to its Board of Directors
GlobeNewswire
DIAGNOS Announces Closing of Second and Final Tranche of Private Placement
GlobeNewswire
DIAGNOS Announces Grant of Stock Options
GlobeNewswire
DIAGNOS Welcomes Mr. Michael Braeuel to its Board of Directors
GlobeNewswire
DIAGNOS Announces Closing of First Tranche of Private Placement
GlobeNewswire
Diagnos Announces Variation in One Insider Ownership of Common Shares
GlobeNewswire
DIAGNOS recognized as a Top TSX Venture Exchange Company
GlobeNewswire
DIAGNOS Appoints New Chief Operating Officer
The Globe and Mail
Tuesday’s analyst upgrades and downgrades
GlobeNewswire
DIAGNOS Secures Exclusive Distribution Agreement for Canada with EssilorLuxottica, a Global Leader in Vision Care
GlobeNewswire
DIAGNOS Announces Closing of Private Placement
GlobeNewswire
DIAGNOS AI Retina Analysis is being deployed across Canada’s Largest Specialist Care Provider in Diabetes & Endocrinology
Globe Newswire
DIAGNOS Announces the Start of the Deployment of its Pathology Detection Systems in the Retail Clinics of Farmacias Benavides, a Member of Walgreens Boots Alliance
Globe Newswire
DIAGNOS Announces the Deployment of its Age-Related Macular Degeneration Detection Application Into the Optometry Clinics of IRIS, The Visual Group
Globe Newswire
DIAGNOS and the CHUM are launching the testing phase of autonomous artificial intelligence solutions dedicated to diabetic retinopathy screening
Globe Newswire
DIAGNOS Announces a Contract with Farmacias Benavides, a Member of Walgreens Boots Alliance in Mexico
Globe Newswire
DIAGNOS Announces Closing of Private Placement and New Marketing Director
Globe Newswire
CAN Health Network and Quebec-Based DIAGNOS Announce Life-Changing Diabetic Retinopathy Screening Program Partnership
Globe Newswire
DIAGNOS Announces Closing of Private Placement
Globe Newswire
DIAGNOS Successfully Completes ISO / MDSAP Audit
Globe Newswire
DIAGNOS Provides Corporate Update for 2021 and Outlook for 2022
Globe Newswire
DIAGNOS will start a clinical trial study in the USA commencing December 6th, 2021 for early detection and prevention of Stroke using CARA-STROKE.

Profile

Diagnos Inc is engaged in the provision of software-based interpretation services to assist health specialists in the detection of diabetic retinopathy. The company provides image analysis services through CARA (Computer Assisted Retinal Analysis). It operates in the business segment of Healthcare services. The company has a business presence in Canada, the United States, UAE, Saudi Arabia, Mexico, Costa Rica, and others. The company's key revenue is derived from Canada.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.